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Correction to: British Journal of Cancer (2008) 98, 596–603.
doi: 10.1038/sj.bjc.6604197
Owing to an error on the part of the authors, mistakes were made
in the assignment of protein names to the peptides found as
biomarkers in the above paper.
The last two graphs in Figure 1 entitled ‘VIM_5’ (lower middle)
and ‘VIM_6’ (lower right) should be removed. They are not
vimentin-derived peptide signals. The caption of Figure 1B should
also be corrected from ‘These six peptide signals’ to ‘These four
peptide signals’. Also in the last part of the caption, ‘Po8.3 10
 6’
should be changed as ‘Po3.8 10
 7’.
In the legend to Figure 3, an error was made in the description of
the two graphs (A and B), with the graphs being transposed. The
first line of the legend should have read: ‘Kaplan–Meier curves for
disease-free survival after complete resection in patients with stage
I lung adenocarcinoma who received PAC with uracil-tegafur (B),
or did not receive any PAC (A).’
The last two rows of Table 3 should also be removed. The amino-
acid sequences assigned as ‘VIM_5’ and ‘VIM_6’ should not be
assigned as Vimentin.
Table 3 Amino-acid sequences from the selected peptide ion signals
Name Fraction Sequence
Myosin, heavy polypeptide 9, non-muscle
MYH9_1 Insoluble IRELESQISELQEDLESER
MYH9_2 Insoluble KANLQIDQINTDLNLER
MYH9_3 Insoluble HEMPPHIYAITDTAYR
Vimentin
VIM_1 Insoluble ETNLDSLPLVDTHSK
VIM_2 Insoluble NLQEAEEWYK
VIM_3 Insoluble LGDLYEEEMR
VIM_4 Insoluble LLQDSVDFSLADAINTEFK
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Figure 1 Comparison of the intensity of peptide signals originating from the same protein molecule in each group detected by LC-MS. The vertical axis
indicates normalised signal intensity measured by LC-MS. In each box plot, the upper and lower sides of the box represent the upper and the lower quartile
values (Q3/Q1), and the upper and lower horizontal bars outside the box indicate the upper and the lower adjacent values (UAV/LAV). Note that UAV is
the largest observation value that is less than or equal to Q3þ1.5 (Q3–Q1), and LAV is the smallest observation greater than or equal to Q1–
1.5 (Q3–Q1). Black triangle marks represent the median values, and black square marks represent outliers. U0R0: patients without PAC showing no
recurrence within 5 years after surgery. U0R1: patients without PAC showing recurrence within 5 years after surgery. U1R0: patients who received PAC with
uracil-tegafur and showed no recurrence within 5 years after surgery. U1R1: patients who received PAC with uracil-tegafur and showed recurrence within 5
years after surgery. (A) These three peptide signals were shown by MS/MS to have originated from myosin IIA. There was a significant difference between
the U1R1 and the other groups (Po9.7 10
 7). (B) These four peptide signals were shown by MS/MS to have originated from vimentin. There was also a
significant difference between the U1R1 and the other groups (Po3.8 10
 7).
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